Find Out if You Qualify for a Financial Reward by filling out the form below.
Investigation Details
On July 30, 2024, PepGen released data from its ongoing Phase 2 trial of its drug candidate PGN-EDO51. On this news, PepGen stock fell over 45% during intraday trading on July 31, 2024.
| Ticker Symbol | Company Name | Join Deadline | Join |
|---|---|---|---|
| PCRX | Pacira BioSciences, Inc. | March 14, 2025 | Join |
| NVO | Novo Nordisk A/S | March 25, 2025 | Join |
| GO | Grocery Outlet Holding Corp. | March 31, 2025 | Join |
| NEM | Newmont Corporation | April 01, 2025 | Join |
| GSK | GSK plc | April 07, 2025 | Join |
| NTLA | Intellia Therapeutics, Inc. | April 14, 2025 | Join |
| MRK | Merck & Co., Inc. | April 14, 2025 | Join |
| VG | Venture Global, Inc. | April 18, 2025 | Join |
| STZ | Constellation Brands, Inc. | April 21, 2025 | Join |
| SWKS | Skyworks Solutions, Inc. | May 05, 2025 | Join |